Navigation Links
GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014

OXFORD, England, January 7, 2014 /PRNewswire/ --

GlySure reaches major milestone in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its European regulatory trial at the OneMedForum 2014 conference on January 13, 2014, in San Francisco.

OneMedForum 2014 will be the first time that the GlySure CEO Christopher Jones publicly presents the results of the multi-center CE Mark trial, which comprised 34 post surgery cardiac intensive care unit patients.

GlySure's announcement of the trial results marks the culmination of an exceptional year for the UK-based company. Since the start of 2013, GlySure has completed the development of the commercial version of its CBG monitor and sensor, secured ISO 13485 certification, completed a successful pilot trial on 24 cardiac ICU patients, recruited its European Director of Clinical Affairs, and delivered a successful European regulatory trial.

GlySure is currently compiling its CE Mark Technical File submission, which is the next step toward securing marketing approval of its CGBM technology in Europe. The company anticipates that it will make this submission in Q1.

"We are extremely pleased with the trial results demonstrating the ability to provide true continuous blood glucose monitoring on patients throughout their stay in cardiac intensive care," said GlySure CEO Christopher Jones. "We look forward to sharing these positive findings with the industry at OneMedForum in San Francisco next week."

OneMedForum 2014 will focus on areas of greatest investment opportunity in therapeutics, devices, diagnostics and health information and will also showcase the most promising microcap public companies and high growth private (pre-IPO) companies. More than 100 companies and 1,300 investors attend the annual event.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe.

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870,

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127,

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
2. PAREXEL International To Present At JP Morgan Healthcare Conference
3. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
4. Accuray to Present at JP Morgan 32nd Annual Healthcare Conference
5. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
6. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
7. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
8. Gateway Analytical to Present Latest Research at the Drug Delivery to the Lungs Conference in Edinburg, Scotland
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
Breaking Biology News(10 mins):